ÂÜÀòÂÒÂ×

Rodolphe Barrangou has extensive work experience in the field of biosciences and academia. Rodolphe is currently a T.R. Klaenhammer Distinguished Professor at North Carolina State University since February 2013. In addition, they serve as the Editor In Chief of The CRISPR Journal since November 2017. Rodolphe is also a Co-Founder and CSO of Ancilia Biosciences since December 2019. Furthermore, they are a member of the Scientific Advisory Board at Invaio Sciences since April 2019 and at Inari since June 2018. Rodolphe co-founded Intellia Therapeutics, Inc. in July 2014. From July 2016 to July 2018, they served as a co-founder, CSO, and SAB Chairman at Locus Biosciences, Inc. Additionally, they worked as an Adjunct Professor at Penn State University from January 2010 to January 2016. Rodolphe also served as the Chairman of the BOD at Caribou Biosciences from 2013 to 2016. Prior to that, they held the position of R&D Director at DuPont from February 2005 to February 2013.

Rodolphe Barrangou's education history began in 1996 when they enrolled in the Université de Technologie de Compiègne (UTC) and pursued a Master of Science degree in Biological Engineering, completing it in the year 2000. Following this, from 1998 to 2000, they attended North Carolina State University and obtained another Master of Science degree, this time in Food Science.

Continuing their academic journey, Barrangou enrolled at North Carolina State University in 2001 and spent the next three years completing their Ph.D. in Functional Genomics, finishing in 2004. Finally, in 2009, they pursued an MBA, specializing in Executive Management, from the Wisconsin School of Business, which they completed in 2011.